NAS:IRWD (USA) Also trade in: Germany

Ironwood Pharmaceuticals Inc

$ 11.15 -0.11 (-0.98%)
Volume: 1,777,228 Avg Vol (1m): 1,550,905
Market Cap $: 1.74 Bil Enterprise Value $: 2.02 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -15.79
Net Current Asset Value -2.57
Tangible Book -1.54
Projected FCF -14.98
Median P/S Value 20.31
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.29
Cash-To-Debt ranked lower than
69.85% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
IRWD: 0.29
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.29, Med: 1.41, Max: 420.39
Current: 0.29
0.29
420.39
Equity-to-Asset -0.65
Equity-to-Asset ranked lower than
96.95% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
IRWD: -0.65
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.86, Med: 0.18, Max: 0.74
Current: -0.65
-1.86
0.74
Debt-to-Equity -1.71
Debt-to-Equity ranked lower than
100.00% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
IRWD: -1.71
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -22.55, Med: 0.1, Max: 80.69
Current: -1.71
-22.55
80.69
Debt-to-EBITDA -1.62
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
IRWD: -1.62
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -11.91, Med: -0.93, Max: -0.01
Current: -1.62
-11.91
-0.01
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.74
DISTRESS
GREY
SAFE
Beneish M-Score -3.61
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -115.96%
WACC 16.11%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -34.70
Operating Margin ranked lower than
80.02% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
IRWD: -34.7
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1101.36, Med: -78.44, Max: -15.21
Current: -34.7
-1101.36
-15.21
Net Margin % -86.22
Net Margin ranked lower than
79.43% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
IRWD: -86.22
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1192.31, Med: -96.93, Max: -29.83
Current: -86.22
-1192.31
-29.83
ROA % -64.85
ROA ranked lower than
76.92% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
IRWD: -64.85
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -107.22, Med: -31.59, Max: -12.3
Current: -64.85
-107.22
-12.3
ROC (Joel Greenblatt) % -664.45
ROC (Joel Greenblatt) ranked lower than
83.04% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
IRWD: -664.45
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -672.27, Med: -251.44, Max: -159
Current: -664.45
-672.27
-159
3-Year Total Revenue Growth Rate 32.30
3-Year Revenue Growth Rate ranked higher than
95.65% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
IRWD: 29.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -41.1, Med: 29.2, Max: 112.1
Current: 29.2
-41.1
112.1
3-Year Total EBITDA Growth Rate -32.10
3-Year EBITDA Growth Rate ranked higher than
80.54% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
IRWD: -29
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -51.9, Med: 4.4, Max: 58.2
Current: -29
-51.9
58.2
3-Year EPS w/o NRI Growth Rate -22.60
3-Year EPS w/o NRI Growth Rate ranked higher than
65.01% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
IRWD: -22.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» IRWD's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IRWD

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare SZSE:300630 NAS:SUPN TSX:APHA SHSE:600062 NAS:HRTX HKSE:02616 XLJU:KRKG SZSE:000078 NAS:ENDP BOM:524494 TSE:4521 NAS:TCDA SHSE:603567 SHSE:600267 HKSE:00867 NAS:PCRX SZSE:000650 SHSE:600079 SZSE:300725 TSX:HEXO
Traded in other countries I76.Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
Forward PE Ratio 54.64
Forward P/E ranked lower than
100.00% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
IRWD: 54.64
Ranked among companies with meaningful Forward P/E only.
N/A
PS Ratio 4.95
PS Ratio ranked lower than
79.35% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
IRWD: 4.95
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.93, Med: 9.01, Max: 63.43
Current: 4.95
2.93
63.43
EV-to-EBIT -7.76
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
IRWD: -7.76
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -50.9, Med: -11.6, Max: -3.5
Current: -7.76
-50.9
-3.5
EV-to-EBITDA -8.08
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
IRWD: -8.08
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -74.2, Med: -13.1, Max: -3.7
Current: -8.08
-74.2
-3.7
EV-to-Revenue 5.84
EV-to-Revenue ranked lower than
78.36% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
IRWD: 5.84
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.2, Med: 10.1, Max: 65.6
Current: 5.84
4.2
65.6
Current Ratio 1.70
Current Ratio ranked higher than
58.95% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
IRWD: 1.7
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.7, Med: 4.34, Max: 9.64
Current: 1.7
1.7
9.64
Quick Ratio 1.70
Quick Ratio ranked higher than
66.20% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
IRWD: 1.7
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.7, Med: 4.26, Max: 9.04
Current: 1.7
1.7
9.04
Days Inventory 8.13
Days Inventory ranked higher than
95.63% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
IRWD: 8.13
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 4.1, Med: 730.81, Max: 75342.08
Current: 8.13
4.1
75342.08
Days Sales Outstanding 76.56
Days Sales Outstanding ranked lower than
57.53% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
IRWD: 76.56
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 3.61, Med: 70.37, Max: 133.06
Current: 76.56
3.61
133.06
Days Payable 131.12
Days Payable ranked higher than
94.85% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
IRWD: 131.12
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 131.12, Med: 673.43, Max: 261248.75
Current: 131.12
131.12
261248.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.50
3-Year Share Buyback Rate ranked higher than
66.02% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
IRWD: -2.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -144.5, Med: -6.9, Max: -2.2
Current: -2.5
-144.5
-2.2

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.55
Price-to-Median-PS-Value ranked higher than
69.85% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
IRWD: 0.55
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.38, Med: 1.01, Max: 5.78
Current: 0.55
0.38
5.78
Earnings Yield (Joel Greenblatt) % -12.88
Earnings Yield (Greenblatt) ranked lower than
73.01% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
IRWD: -12.88
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -28.6, Med: -8.6, Max: -2
Current: -12.88
-28.6
-2

More Statistics

Revenue (TTM) (Mil) $ 346.21
EPS (TTM) $ -1.94
Beta 2.55
Volatility % 53.31
52-Week Range $ 7.59 - 17.74
Shares Outstanding (Mil) 155.62

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y